Alimatravir is in late-stage clinical trials and adds, once registered and approved, another weapon to South Africa's arsenal against high infection rates
Khulekani Magubane is a Financial Reporter at Business Times. He specializes in finance, investment, and energy sectors, covering topics such as renewable energy, mining operations, and commodities markets. Khulekani's insights and analyses have been featured in prominent publications including Daily Dispatch, News24 Business, HeraldLIVE, Business Day, Sowetan, Sunday Times, The Times, and BusinessLIVE.














